Lido Advisors
HRTX icon

Lido Advisors’s Heron Therapeutics HRTX Stock Holding History

Lido Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,072
Closed -$12.7K – 2028
2025
Q4 		$12.7K Hold
10,072
– – ﹤0.01% 1917
2025
Q3 		$12.7K Buy
10,072
+72
+0.7% +$114 ﹤0.01% 1821
2025
Q2 		$20.7K Hold
10,000
– – ﹤0.01% 1637
2025
Q1 		$22K Hold
10,000
– – ﹤0.01% 1490
2024
Q4 		$15.3K Sell
10,000
-35,308
-78% -$57.2K ﹤0.01% 1487
2024
Q3 		$90.2K Hold
45,308
– – ﹤0.01% 1403
2024
Q2 		$159K Hold
45,308
– – ﹤0.01% 1311
2024
Q1 		$126K Sell
45,308
-1,627
-3% -$4.09K ﹤0.01% 1311
2023
Q4 		$79.8K Buy
46,935
+7,500
+19% +$8.26K ﹤0.01% 1296
2023
Q3 		$40.6K Buy
39,435
+2,500
+7% +$3.56K ﹤0.01% 1177
2023
Q2 		$42.8K Buy
36,935
+1,627
+5% +$2.9K ﹤0.01% 1187
2023
Q1 		$53.3K Hold
35,308
– – ﹤0.01% 1113
2022
Q4 		$88.3K Hold
35,308
– – ﹤0.01% 970
2022
Q3 		$148K Hold
35,308
– – ﹤0.01% 901
2022
Q2 		$98K Hold
35,308
– – ﹤0.01% 904
2022
Q1 		$201K Buy
35,308
+16,576
+88% +$121K ﹤0.01% 950
2021
Q4 		$171K Hold
18,732
– – ﹤0.01% 967
2021
Q3 		$200K Hold
18,732
– – ﹤0.01% 924
2021
Q2 		$291K Buy
+18,732
New +$298K ﹤0.01% 733

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Lido Advisors's HRTX Position: Q1 2026 in Review

Lido Advisors sold out of Heron Therapeutics (HRTX) in Q1 2026, closing a stake of 10,072 shares — an estimated $12.7K sold.

Lido Advisors first reported a position in HRTX in Q2 2021 and held it in 19 quarters. The position peaked at $291K in Q2 2021. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Lido Advisors reported no remaining Heron Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Lido Advisors sold 10,072 Heron Therapeutics shares in Q1 2026, an estimated $12.7K.
  • Lido Advisors first reported a position in Heron Therapeutics in Q2 2021 and held it in 19 quarters.
  • Lido Advisors's Heron Therapeutics position peaked at $291K in Q2 2021.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Lido Advisors's 13F filing for Q1 2026, filed 13 May 2026.